As part of the Vignelli Center’s MEDdesign initiative, Professor Bruce Ian Meader conceived and developed a poster project for his graduate Information Design course. Each student selected a human ...
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative ColitisCarlsbad, CA, ...
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the ...
Gain Therapeutics, Inc., a clinical-stage biotechnology company, announced that it will present its lead drug candidate, GT-02287, at the International Association of Parkinsonism and Related ...
MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its submission entitled “Lomecel ...
AMSTERDAM--(BUSINESS WIRE)--VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through ...
The Pennsylvania Department of Health has announced the commencement of the 2026 Student Lyme Disease Prevention Art ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its three posters at the ...
- Treefrog will present two posters on their cell therapy program in Parkinson's Disease and their proprietary encapsulation technology, C-Stem™ - TreeFrog is a cell therapy company with a lead ...
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference Provided by GlobeNewswire Apr 24, 2025 5:01am ...
Session: Oral Poster Presentation – Guided Poster TourSession Date: Saturday, May 10, 2025Session Time: 8:00-9:00 a.m. EST About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in ...
Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results